glp-1 for chronic pain and GIP: Magic bullet musculoskeletal diseases? GLP-1 Medications for Arthritis &

Table of Contents 1 Preface 2 Executive Summary 3 Overview of GLP-1 Agonists 4 Patient Profile: GLP-1 Agonists 5 GLP-1 Agonists: Epidemiology Snapshot 6 GLP-1 Agonists: Market Dynamics 7 GLP-1 Agonists: Key Facts Covered 8 GLP-1 Agonists, Drug Pipeline Assessment 9 Drug Pipeline Comparative Analysis 10 GLP-1 Agonists Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs) 11 GLP-1 Agonists Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs) 12 GLP-1 Agonists Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs) 13 GLP-1 Agonists Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs) 14 GLP-1 Agonists, Key Drug Pipeline Companies 15 Regulatory Framework for Drug Approval, By Region 16 Terminated or Suspended Pipeline Products

Notably, eight taxa at the genus level were significantly abundant in the TMAO-producer group (FDR 10 M) that grouped to low producers after carnitine supplementation

Kohn, A

Aringazina RA, Akhmetova GK, Sharipova GM

These findings not only provide deeper insight into the molecular foundations of aging but also open promising avenues for research into interventions aimed at extending healthspan and investigating age-associated diseases